Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2289-2296

  Carvajal, Richard D ^a,b   Lawrence, Donald P ^c   Weber, Jeffrey S ^d   Gajewski, Thomas F ^e   Gonzalez, Rene ^f   Lutzky, Jose ^g   O'Day, Steven J ^h   Hamid, Omid ⁱ   Wolchok, Jedd D ^a,b   Chapman, Paul B ^a,b   Sullivan, Ryan J ^c   Teitcher, Jerrold B ^a   Ramaiya, Nikhil ^j   Giobbie Hurder, Anita ^j   Antonescu, Cristina R ^a   Heinrich, Michael C ^k   Bastian, Boris C ^l   Corless, Christopher L ^k   Fletcher, Jonathan A ^j   Hodi, F Stephen ^j  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g Mount Sinai Comprehensive Cancer Center   (United States)

^h Beverly Hills Cancer Center   (United States)

ⁱ Angeles Clinic and Research Institute   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; PANCREAS ENZYME; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPONATREMIA; MALE; METASTATIC MELANOMA; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ONCOGENE C KIT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; DRUG RESISTANCE; GENETICS; MELANOMA; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84941992041     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1630     Document Type: Article

References (29)

1. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6.
2. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51.
3. Satzger I, Kuttler U, Volker B, Schenck F, Kapp A, Gutzmer R. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy-case report and review of the literature. Dermatology 2010;220:77-81.
4. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008;21:492-3.
5. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8:2079-85.
6. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008;5:737-40.
7. Zhu Y, Si L, Kong Y, Chi Z, Yuan X, Cui C, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009;27:15s (suppl; abstr e20017).
8. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34.
9. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
10. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013;31:3182-90.
11. Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC. Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 2012;18:1457-63.
12. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, Kerr L, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102:1219-23.
13. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74.
14. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
15. Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012; 30:2377-83.
16. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295-302.
17. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.
18. Cullinane C, Natoli A, Hui Y, Conus N, Jackson S, Bruggen J, et al. Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. Mol Cancer Ther 2010;9:1461-8.
19. Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009;15:6862-70.
20. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008;112:1005-12.
21. Reinwald M, Schleyer E, Kiewe P, Blau IW, Burmeister T, Pursche S, et al. Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation. BioMed Res Int 2014;2014:637059.
22. Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011;117:4633-41.
23. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21: 4342-9.
24. Cho JH, Kim KM, Kwon M, Kim JH, Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2012;30:2008-14.
25. Blay J, Shen L, Kang Y, Rutkowski P, Qin S, Nosov D, et al. Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST). J Clin Oncol 31, 2013 (suppl; abstr 10501).
26. Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23:1680-7.
27. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008;21:476-84.
28. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev 2007;17:3-7.
29. Si L, Xu X, Kong Y, Flaherty KT, Chi Z, Cui C, et al. Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol 2012;30:e37-40.